Cargando…

Cucurbitacin IIa: a novel class of anti-cancer drug inducing non-reversible actin aggregation and inhibiting survivin independent of JAK2/STAT3 phosphorylation

Mostrar otras versiones (1)

BACKGROUND: Cucurbitacin (Cuc) and triterpene-derived natural products exhibit anti-cancer potential in addition to their conspicuous anti-bacterial and anti-inflammatory activity. Recently, inhibition of Janus kinase 2 (JAK2)/signal transducer and activator of transcription 3 (STAT3) signaling was...

Descripción completa

Detalles Bibliográficos
Autores principales:	Boykin, C, Zhang, G, Chen, Y-H, Zhang, R-W, Fan, X-E, Yang, W-M, Lu, Q
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2011
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3048206/ https://www.ncbi.nlm.nih.gov/pubmed/21304528 http://dx.doi.org/10.1038/bjc.2011.10

Ejemplares similares

Cucurbitacin IIa: a novel class of anti-cancer drug inducing non-reversible actin aggregation and inhibiting survivin independent of JAK2/STAT3 phosphorylation
por: Boykin, C, et al.
Publicado: (2012)

Atiprimod blocks STAT3 phosphorylation and induces apoptosis in multiple myeloma cells
por: Amit-Vazina, M, et al.
Publicado: (2005)

Survivin and XIAP: two valuable biomarkers in medullary thyroid carcinoma
por: Werner, Thomas A, et al.
Publicado: (2016)

Extracellular, cell-permeable survivin inhibits apoptosis while promoting proliferative and metastatic potential
por: Khan, S, et al.
Publicado: (2009)

Oxidative stress specifically downregulates survivin to promote breast tumour formation
por: Pervin, S, et al.
Publicado: (2013)

Characterisation of the anti-apoptotic function of survivin-ΔEx3 during TNFα−mediated cell death
por: Malcles, M-H, et al.
Publicado: (2007)

Dual inhibition of survivin and MAOA synergistically impairs growth of PTEN-negative prostate cancer
por: Xu, S, et al.
Publicado: (2015)

Centrosome amplification induced by survivin suppression enhances both chromosome instability and radiosensitivity in glioma cells
por: Saito, T, et al.
Publicado: (2008)

Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugs
por: Iwasa, T, et al.
Publicado: (2010)

Withacnistin inhibits recruitment of STAT3 and STAT5 to growth factor and cytokine receptors and induces regression of breast tumours
por: Zhang, X, et al.
Publicado: (2014)

Enzastaurin has anti-tumour effects in lung cancers with overexpressed JAK pathway molecules
por: Shimokawa, T, et al.
Publicado: (2012)

STAT3 is required but not sufficient for EGF receptor-mediated migration and invasion of human prostate carcinoma cell lines
por: Zhou, W, et al.
Publicado: (2006)

Stat3 activation in human endometrial and cervical cancers
por: Chen, C-L, et al.
Publicado: (2007)

Treatment with Imatinib in NSCLC is associated with decrease of phosphorylated PDGFR-β and VEGF expression, decrease in interstitial fluid pressure and improvement of oxygenation
por: Vlahovic, G, et al.
Publicado: (2006)

p28, A first in class peptide inhibitor of cop1 binding to p53
por: Yamada, T, et al.
Publicado: (2013)

A potent nonporphyrin class of photodynamic therapeutic agent: cellular localisation, cytotoxic potential and influence of hypoxia
por: Gallagher, W M, et al.
Publicado: (2005)

Elevated phosphorylation and activation of PDK-1/AKT pathway in human breast cancer
por: Lin, H-J, et al.
Publicado: (2005)

STAT3 inhibitor WP1066 as a novel therapeutic agent for renal cell carcinoma
por: Horiguchi, A, et al.
Publicado: (2010)

R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and haematological malignancies
por: Arts, J, et al.
Publicado: (2007)

Activation of IFN/STAT1 signalling predicts response to chemotherapy in oestrogen receptor-negative breast cancer
por: Legrier, Marie-Emmanuelle, et al.
Publicado: (2016)

Class III β-tubulin expression and in vitro resistance to microtubule targeting agents
por: Stengel, C, et al.
Publicado: (2010)

Impaired T-bet-pSTAT1α and perforin-mediated immune responses in the tumoral region of lung adenocarcinoma
por: Andreev, Katerina, et al.
Publicado: (2015)

Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma
por: Shen, Y-C, et al.
Publicado: (2013)

The expression of platelet-activating factor receptor modulates the cisplatin sensitivity of ovarian cancer cells: a novel target for combination therapy
por: Yu, Y, et al.
Publicado: (2014)

Increased expression of class III β-tubulin in castration-resistant human prostate cancer
por: Terry, S, et al.
Publicado: (2009)

Effects of VEGFR-3 phosphorylation inhibitor on lymph node metastasis in an orthotopic diffuse-type gastric carcinoma model
por: Yashiro, M, et al.
Publicado: (2009)

LLL-3 inhibits STAT3 activity, suppresses glioblastoma cell growth and prolongs survival in a mouse glioblastoma model
por: Fuh, B, et al.
Publicado: (2009)

Molecular targets for anticancer redox chemotherapy and cisplatin-induced ototoxicity: the role of curcumin on pSTAT3 and Nrf-2 signalling
por: Fetoni, A R, et al.
Publicado: (2015)

The rexinoid, bexarotene, prevents the development of premalignant lesions in MMTV-erbB2 mice
por: Li, Y, et al.
Publicado: (2008)

Immunotherapy augments the effect of 5-azacytidine on HPV16-associated tumours with different MHC class I-expression status
por: Šímová, J, et al.
Publicado: (2011)

Cucurbitacin E and I target the JAK/STAT pathway and induce apoptosis in Sézary cells
por: Brouwer, Isabella J., et al.
Publicado: (2020)

Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer
por: Chang, Q, et al.
Publicado: (2008)

Human leukocyte antigen class I expression is an independent prognostic factor in advanced ovarian cancer resistant to first-line platinum chemotherapy
por: Shehata, M, et al.
Publicado: (2009)

Inhibition of VEGF expression through blockade of Hif1α and STAT3 signalling mediates the anti-angiogenic effect of melatonin in HepG2 liver cancer cells
por: Carbajo-Pescador, S, et al.
Publicado: (2013)

Interleukin-6 mediated upregulation of CYP1B1 and CYP2E1 in colorectal cancer involves DNA methylation, miR27b and STAT3
por: Patel, S A A, et al.
Publicado: (2014)

Characterisations of human prostate stem cells reveal deficiency in class I UGT enzymes as a novel mechanism for castration-resistant prostate cancer
por: Williamson, S C, et al.
Publicado: (2013)

Gambogic acid synergistically potentiates cisplatin-induced apoptosis in non-small-cell lung cancer through suppressing NF-κB and MAPK/HO-1 signalling
por: Wang, L-H, et al.
Publicado: (2014)

In vivo high-resolution fluorescence microendoscopy for ovarian cancer detection and treatment monitoring
por: Zhong, W, et al.
Publicado: (2009)

Restoration of PPP2CA expression reverses epithelial-to-mesenchymal transition and suppresses prostate tumour growth and metastasis in an orthotopic mouse model
por: Bhardwaj, A, et al.
Publicado: (2014)

A functional bioassay to determine the activity of anti-VEGF antibody therapy in blood of patients with cancer
por: Wentink, Madelon Q, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_k6g06c1uim4nl8o67hp9qfa2ju